Iksuda Therapeutics’ £29.6 Million Series A Financing Round

Ashfords advised life sciences company Iksuda Therapeutics on the deal. Bird & Bird advised Mirae Asset Capital, Celltrion and Premier Partners.Iksuda is the developer of a…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Federica Tiefenthaler

Author: Federica Tiefenthaler

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Iksuda Therapeutics’ £29.6 Million Series A Financing Round

Ashfords advised life sciences company Iksuda Therapeutics on the deal. Bird & Bird advised Mirae Asset Capital, Celltrion and Premier Partners.Iksuda is the developer of a…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Federica Tiefenthaler

Author: Federica Tiefenthaler

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here